Physician profile
Mark Mclaughlin
NPI 1386164507
$3,031.80
in general payments reported to CMS, 2019-2025
17 companies · $514 in 2025
The $514 reported for 2025 was more than what 75% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.67 · 2020: $33.22 · 2021: $63.85 · 2022: $504 · 2023: $716 · 2024: $1,185 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,099 · Travel and Lodging: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,099.06 |
| Travel and Lodging | $315.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $902.52 | 2024-2025 | Barrigel |
| Palette Life Sciences, INC. | $635.80 | 2023 | |
| Accuray Incorporated | $333.20 | 2024 | |
| Boston Scientific Corporation | $332.48 | 2022-2025 | Spaceoar Vue System - 10ml |
| Astrazeneca Pharmaceuticals Lp | $186.47 | 2021-2025 | Tagrisso |
| Bard Peripheral Vascular, INC. | $124.06 | 2022 | |
| Bioprotect Medical, INC. | $121.57 | 2024 | Bioprotect Balloon Implant System |
| Gt Medical Technologies, INC | $119.92 | 2022 | |
| Seagen INC. | $59.75 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $45.93 | 2024 | Orgovyx |
| Genentech USA, INC. | $36.48 | 2023-2024 | Tecentriq, Lunsumio, Polivy |
| Glaxosmithkline, LLC. | $33.22 | 2020 | |
| Accord Healthcare, INC. | $32.16 | 2024 | |
| Kyowa Kirin, INC. | $20.31 | 2023 | Poteligeo |
| Mirati Therapeutics, INC. | $17.32 | 2024 | Krazati |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $16.67 | 2019 | |
| Merck Sharp & Dohme LLC | $13.94 | 2023 | Keytruda, Welireg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.